Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01205061 · ClinicalTrials.gov registry record · NA
Emervel® Deep Lidocaine vs. Juvederm® Ultra Plus in Treatment of Moderate to Severe Facial Wrinkles and Folds
A NA study, sponsored by Galderma R&D.
- Completed
- Registry status
- NA
- Development phase
- 162
- Enrollment target
NCT01205061: Completed NA study, sponsored by Galderma R&D.
NCT01205061 is a NA study that has completed, run by Galderma R&D. The registered enrollment target is 162 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01205061, a NA study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- NA
- Development phase
- 162 participants
- Enrollment target
Study Summary
The purpose of the study was to compare the effectiveness and safety of Emervel Deep Lidocaine versus Juvederm Ultra Plus in the treatment of moderate to severe facial wrinkles and folds.
Primary Outcome
WSRS is a validated 5-point reference scale with photographs that classifies deep facial wrinkles (nasolabial folds). WSRS represents clinically meaningful change in NLF severity from the adjacent grades where 1= absent (no visible fold; continuous skin line), 2 = mild (shallow but visible fold with a slight indentation; minor facial feature; implant expected to produce a slight improvement in appearance), 3 = excellent (correction is expected from injectable implant), 4 = severe (very long and
Interventions
- DEVICE Emervel Deep Lidocaine
- DEVICE Juvederm Ultra Plus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2010-09-27 |
| Est. Completion | 2012-01-12 |
| Phase | NA |
What the finished NCT01205061 record still lists
NCT01205061 is an interventional study that assigns participants to a tested intervention. The registered 162 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Emervel Deep Lidocaine is the first listed.
NCT01205061 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01205061 about?
NCT01205061 is a clinical study titled "Emervel® Deep Lidocaine vs. Juvederm® Ultra Plus in Treatment of Moderate to Severe Facial Wrinkles and Folds". The purpose of the study was to compare the effectiveness and safety of Emervel Deep Lidocaine versus Juvederm Ultra Plus in the treatment of moderate to severe facial wrinkles and folds.
What is the current status of trial NCT01205061?
This trial is currently completed. It is a NA study. The enrollment target is 162 participants. The study started on 2010-09-27. Estimated completion is 2012-01-12.
What interventions are being tested in trial NCT01205061?
The interventions under investigation include: Emervel Deep Lidocaine (DEVICE), Juvederm Ultra Plus (DEVICE).
Who is sponsoring clinical trial NCT01205061?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01205061's enrollment target sits among peer trials
162 627th of 2000 higher than 1,373 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02347111 · 162 participants · Phase 4
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
- NCT02610426 · 162 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
- NCT05040711 · 162 participants · NA
mHealth Mindfulness With Patients With Serious Illness and Their Caregivers
- NCT05514717 · 162 participants · Phase 1
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI